NCT02518529View on ClinicalTrials.gov

Study to Assess Tolerability and Safety and Antibody Response to G17DT in Gastric Cancer Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

February 28, 2001

Primary Completion Date

December 31, 2002

Study Completion Date

December 31, 2002

Conditions
Gastric Cancer
Interventions
BIOLOGICAL

G17DT

Sponsors
All Listed Sponsors
collaborator

PPD Development, LP

INDUSTRY

collaborator

ChapelPharma Ltd

UNKNOWN

lead

Cancer Advances Inc.

INDUSTRY